(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

INHATARGET

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

INHATARGET

ST13

US500000088312441

Class

1, 5, 10, 42

Filing

88312441

Registration

6005331

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

31

Latest update

06/25/2026

Trademark type

Word

Nice classes

1, 5, 10, 42

Filing date

02/22/2019

Registration date

03/10/2020

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

03/10/2020

Last transaction

06/25/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Foreign priority

Drawing code

4

Owner type

99

Owner location

Bruxelles, BE

Examiner

EULIN, INGRID C

Current location

Historical data usage

Holders and representatives

Holders

U. B. (pessoa física)

Representatives

Clifford D. Hyra Fresh IP PLC

Technical classification

Nice Classes

Class 1Class 5Class 10Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 1

Chemicals and chemical compositions for use in manufacturing medical preparations

Class 5

Pharmaceutical and veterinary preparations for the treatment of respiratory diseases and disorders; Chemicals and chemical preparations for medical and veterinary useall for administration to human or animal patientschemical reagents for medical or veterinary purposes; Pharmaceutical preparations for pulmonary administrationpharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Preparations for inhalationinhaled pharmaceuticals for the treatment of respiratory diseases and disorders; Powders for inhalerspharmaceutical preparation of inhalation for the treatment of asthma; Powders for asthma inhalerspowder preparation for the treatment of asthma; Powders for transdermal injectionpharmaceutical preparation for use in treating respiratory diseases and disorders; Pharmaceutical and veterinary preparations for oral ingestionpharmaceutical preparation for the treatment of respiratory diseases and disorders through oral ingestion; Pharmaceuticals and veterinary preparations for local administrationmedicated preparations for the treatment of respiratory diseases and disorders

Class 10

Medical and veterinary apparatusarticles and aidsall for the administration of pharmaceutical preparations to human or animal patientsmedical instruments for use in treating respiratory diseases and disorderssurgical instruments and apparatuscatheter for veterinary purposes; Pharmaceutical preparation administration aidsmedical apparatus for introducing pharmaceutical preparations into the human body; devices for applying medicineinhalators sold empty; Inhalers for medical purposes sold empty; Dry powder inhalers for medical purposessold empty; Inhalers for treating asthmanebulizer for administering medication in the form of a mist inhaled into the lungsfor treatment of asthmaparts and fittings for all the aforesaid goods

Class 42

Scientific research and development with respect to pharmaceutical preparationsapparatus and aids for administering medicines; designdevelopment and laboratory testing of new pharmaceutical productsapparatus and aids for administering medicines; Medical and pharmaceutical research services; research in the field of medical administration apparatus and aids; Research in relation to medicine formulationresearch and development of vaccines and medicines; Research and development in the field of pharmaceuticals; product safety testing with respect to medical and pharmaceutical administration apparatus and aids; testing of pharmaceuticals

Publications

History of USPTO decisions and trademark events.

31 publications found

PRA8

POST REGISTRATION ACTION MAILED - SEC. 8

06/25/2026

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

06/21/2026

ES8R

TEAS SECTION 8 RECEIVED

03/10/2026

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

03/10/2025

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

12/08/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

12/08/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

12/08/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

03/10/2020

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

01/16/2020

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

01/06/2020

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

12/24/2019

PUBO

PUBLISHED FOR OPPOSITION

12/24/2019

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

12/04/2019

FIXD

ELECTRONIC RECORD REVIEW COMPLETE

11/15/2019

ERRR

ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED

11/08/2019

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

11/04/2019

XAEC

EXAMINER'S AMENDMENT ENTERED

11/04/2019

ALIE

ASSIGNED TO LIE

11/04/2019

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

11/04/2019

GNEA

EXAMINERS AMENDMENT E-MAILED

11/04/2019

CNEA

EXAMINERS AMENDMENT -WRITTEN

11/04/2019

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/31/2019

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/30/2019

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

10/30/2019

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

09/26/2019

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

05/04/2019

GNRT

NON-FINAL ACTION E-MAILED

05/04/2019

CNRT

NON-FINAL ACTION WRITTEN

05/04/2019

DOCK

ASSIGNED TO EXAMINER

05/03/2019

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

03/14/2019

NWAP

NEW APPLICATION ENTERED

02/26/2019

Continuous trademark protection

Get notified about every new filing that threatens INHATARGET or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.